Rituxan

(Rituximab)

ApprovedMonoclonal antibody

Rituximab is used to treat certain cancers (like lymphoma and leukemia) and autoimmune diseases (like rheumatoid arthritis) by targeting and destroying specific immune cells that are either cancerous or causing harmful inflammation.[2] Rituxan is currently approved and in use across 240 indications[4].[1]

Rituxan is one of 2521 biologic programs targeting Chronic Inflammatory Demyelinating Polyneuropathy. It is currently in Approved.

240

Indications

1,824

Total Trials

Active Trials

2,520

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Chronic Inflammatory Demyelinating PolyneuropathyActive, not recruiting

Japanese EncephalitisActive, not recruiting

Pancreatic NeoplasmActive, not recruiting

Acquired HemophiliaActive, not recruiting

Juvenile DermatomyositisActive, not recruiting

HIV InfectionActive, not recruiting

Systemic Lupus ErythematosusActive, not recruiting

GranulomaActive, not recruiting

Polymyalgia RheumaticaActive, not recruiting

Bullous PemphigoidActive, not recruiting

Chronic Inflammatory Demyelinating PolyneuropathyPhase 3

Active, not recruiting

Japanese EncephalitisPhase 2

Active, not recruiting

Pancreatic NeoplasmPhase 2

Active, not recruiting

Acquired HemophiliaPhase 2

Active, not recruiting

Juvenile DermatomyositisPhase 2

Active, not recruiting

HIV InfectionPhase 2

Active, not recruiting

Systemic Lupus ErythematosusPhase 3

Active, not recruiting

GranulomaPhase 1

Active, not recruiting

Polymyalgia RheumaticaPhase 3

Active, not recruiting

Bullous PemphigoidPhase 3

Active, not recruiting

Showing 10 of 240 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Rituxan

Roche

Approved

1 2

Halaven

Eisai

Preclinical

38 3

Tecentriq

Roche

Preclinical

36 4

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 5

Prolia

Amgen

Preclinical

14 6

Gemzar

GGynecologic Oncology Group

Preclinical

22 7

DATROWAY

Daiichi Sankyo

Preclinical

4 8

Spravato

WWim Janssens

Preclinical

2 9

Avastin

Roche

Preclinical

4 10

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

Lymphoma

NCT02337985

Q4 2026

Phase 2Active, not recruiting

Antibody-Mediated Rejection

NCT05156710

Phase 2Recruiting

Transplantation

NCT04627753

Phase 3Not yet recruiting

Nephrotic Syndrome

NCT05850546

Phase 2Active, not recruiting

Lymphoma

NCT03749018

Phase 2Recruiting

Hepatocellular Carcinoma

NCT06301399

Clinical

Trials by Indication[1]

Lymphoma47 trials

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Completed· Gilead logo

Gilead·Phase 1/2·NCT02348216·307 enrolled

A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g)

Completed· Roche logo

Roche·Phase 2·NCT00517049·49 enrolled

Combination of Oral Fludarabine, Mitoxantrone Und Rituximab Induction Therapy and Rituximab Maintenance Therapy in Follicular B-Cell Lymphoma

Completed·AArbeitsgemeinschaft medikamentoese Tumortherapie·Phase 2·NCT01560117·29 enrolled

Show 44 more trials

Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00493467·31 enrolled

LMBA02 Protocol for Patients With a Burkitt Lymphoma

Unknown status·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT00180882·260 enrolled

Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00075946·545 enrolled

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Active, not recruiting·—·Phase 2·NCT03749018·30 enrolled

Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma

Unknown status· Amgen logo

Amgen·Phase 2·NCT00005959

Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma

Unknown status·CCommissie Voor Klinisch Toegepast Onderzoek·Phase 3·NCT00028717·400 enrolled

S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00005089·71 enrolled

Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed·JJonsson Comprehensive Cancer Center·Phase 1·NCT00040950

Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma

Active, not recruiting·—·Phase 1·NCT02337985·10 enrolled

A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma

Unknown status·CCorixa Corporation·Phase 3·NCT00078598·506 enrolled

Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00712582·96 enrolled

Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma

Completed·LLymphoma Study Association·Phase 2·NCT00169468·48 enrolled

Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00493454·6 enrolled

Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma

Completed·SStanford University·Phase 2·NCT00225212·35 enrolled

A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

Recruiting·UUniversity of Rochester·Phase 2·NCT03758989·40 enrolled

A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant

Terminated·UUniversity of California, San Francisco·Phase 1·NCT00515138·7 enrolled

Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse

Completed·TThe Lymphoma Academic Research Organisation·Phase 1/2·NCT01562990·11 enrolled

Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma

Completed·AAsociacion Espanola de Hematologia y Hemoterapia·Phase 4·NCT01124526·75 enrolled

Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial

Unknown status·QQingdao Central Hospital·Phase 2·NCT05392257·20 enrolled

Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)

Completed·HHaruhiko Fukuda·Phase 2/3·NCT00147121·300 enrolled

Rituximab and DexaBEAM as Salvage Therapy for Relapsed Lymphoma

Completed·GGeorg Hess, MD·Phase 2·NCT02099292·103 enrolled

Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma

Terminated·SSCRI Development Innovations, LLC·Phase 2·NCT02113007·2 enrolled

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL

Completed· Roche logo

Roche·Phase 1/2·NCT02055820·267 enrolled

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma

Completed· GSK logo

GSK·Phase 3·NCT01014208·447 enrolled

Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Completed·FFudan University·Phase 2·NCT00568815·31 enrolled

Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)

Terminated·SSeoul National University Hospital·Phase 2·NCT03578198·12 enrolled

R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial

Completed·GGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea·Phase 2·NCT01133158·61 enrolled

Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma

Completed·GGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea·Phase 2·NCT01015248·60 enrolled

Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma

Unknown status·HHuiqiang Huang·Phase 2·NCT04246359·52 enrolled

Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma

Unknown status·HHenan Cancer Hospital·Phase 2·NCT04938297·100 enrolled

A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Recruiting·FFondazione Italiana Linfomi - ETS·Phase 2·NCT06835530·47 enrolled

Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Completed·UUniversity Hospital Tuebingen·Phase 2·NCT00204659·30 enrolled

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01445535·15 enrolled

Safety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

Terminated·KKeio University·Phase 2·NCT00367497·5 enrolled

Phase II Evaluation of Gemcitabine- Rituximab-Oxaliplatin Combination (GROC) in Relapsed Aggressive Lymphomas

Completed·—·Phase 2·NCT01538641·43 enrolled

Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)

Terminated·MMedical College of Wisconsin·Phase 2/3·NCT00096460·30 enrolled

A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma

Completed· Roche logo

Roche·Phase 3·NCT01200758·410 enrolled

Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma

Unknown status·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02313389·428 enrolled

Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma

Completed· Gilead logo

Gilead·Phase 2·NCT04002401·27 enrolled

Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Completed· Pfizer logo

Pfizer·Phase 2·NCT00867087·64 enrolled

A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma

Not yet recruiting·SShanghai EpimAb Biotherapeutics Co., Ltd.·Phase 1/2·NCT07432022·115 enrolled

Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

Terminated· Pfizer logo

Pfizer·Phase 3·NCT00562965·29 enrolled

Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma

Completed·AAscenta Therapeutics·Phase 2·NCT00440388·23 enrolled

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

Recruiting·MMayo Clinic·Phase 2·NCT06834373·41 enrolled

Diffuse Large B-Cell Lymphoma19 trials

Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT02446457·53 enrolled

Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma

Recruiting·LLi Zhiming·Phase 2·NCT05422066·50 enrolled

Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Terminated· Pfizer logo

Pfizer·Phase 3·NCT02951156·29 enrolled

Show 16 more trials

Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma

Completed·SSamsung Medical Center·Phase 2·NCT02670616·24 enrolled

R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·N/A·NCT05784987·60 enrolled

Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell Lymphoma

Completed·LLymphoma Study Association·Phase 2·NCT00169143·60 enrolled

A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)

Completed· Roche logo

Roche·Phase 1/2·NCT02611323·133 enrolled

A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Completed· Roche logo

Roche·Phase 2·NCT04660799·50 enrolled

STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma

Unknown status·MMathias Witzens-Harig·Phase 2·NCT01653067·88 enrolled

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03003520·46 enrolled

A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT02867566·420 enrolled

RHCACD20MA (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma

Completed·ZZhejiang Hisun Pharmaceutical Co. Ltd.·Phase 2·NCT03485118·137 enrolled

A Phase I/II Study of Diffuse Large B-cell Lymphoma

Not yet recruiting·NNational Health Research Institutes, Taiwan·Phase 1/2·NCT04856137·74 enrolled

A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma

Recruiting·HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 1/2·NCT07124936·97 enrolled

A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Terminated·HHackensack Meridian Health·Phase 1·NCT03136497·10 enrolled

Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT

Completed·GGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea·Phase 2·NCT02692248·64 enrolled

Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)

Unknown status·RRoyal Marsden NHS Foundation Trust·Phase 2·NCT02060656·92 enrolled

A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)

Terminated· Roche logo

Roche·Phase 3·NCT01287741·1,418 enrolled

A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).

Terminated· Roche logo

Roche·Phase 3·NCT04236141·42 enrolled

Chronic Lymphocytic Leukemia11 trials

Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00546377·50 enrolled

Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL)

Withdrawn·UUniversity of Kentucky·Phase 2·NCT00758693

Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT00625729·6 enrolled

Show 8 more trials

Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT01369849·15 enrolled

Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia

Completed·GGerman CLL Study Group·Phase 2·NCT00274989·195 enrolled

Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma

Completed·HHoag Memorial Hospital Presbyterian·Phase 2·NCT00049413

Combined Treatment With Fresh Frozen Plasma and Rituximab (Mabthera) in Patients With Advanced Refractory Chronic Lymphocytic Leukemia

Unknown status·WWolfson Medical Center·Phase 2·NCT00892827·10 enrolled

R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia

Withdrawn·CCABYC·Phase 2·NCT00504491

Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Completed·FFox Chase Cancer Center·Phase 2·NCT00062296·5 enrolled

Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Completed·PPharmatech Oncology·Phase 2·NCT00026351

Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01076556·9 enrolled

Follicular Lymphoma9 trials

A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas

Completed· Roche logo

Roche·Phase 2·NCT01153971·47 enrolled

Comparison of High-Dose Chemotherapy + Rituximab and CHOP + Rituximab in High-Risk Follicular Lymphoma

Unknown status·AAzienda Ospedaliera San Giovanni Battista·Phase 3·NCT00435955·240 enrolled

Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma

Terminated·NNorthwestern University·Phase 1/2·NCT00372905·18 enrolled

Show 6 more trials

Study for Newly Diagnosed Follicular Lymphoma Patients With a Large Tumor Burden

Completed·LLymphoma Study Association·Phase 3·NCT00136552·360 enrolled

Trial of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line

Unknown status·GGrupo Oncológico para el Tratamiento y el Estudio de los Linfomas·Phase 2·NCT01127841·60 enrolled

Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular Lymphoma

Completed·FFondazione Italiana Linfomi - ETS·Phase 2·NCT01523860·76 enrolled

Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma

Unknown status·NNational Research Center for Hematology, Russia·Phase 3·NCT02423837·200 enrolled

Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)

Completed·TThe Lymphoma Academic Research Organisation·Phase 3·NCT02303119·221 enrolled

Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma

Completed·PPharmacyclics LLC.·Phase 2·NCT01980654·80 enrolled

Acute Lymphoblastic Leukemia5 trials

Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01319981·31 enrolled

Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma

Completed·MMehrdad Abedi, MD·Phase 1·NCT02293109·10 enrolled

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT05032183·4 enrolled

Show 2 more trials

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Withdrawn·UUniversity of Washington·Phase 2·NCT02538926

German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·GGoethe University·Phase 4·NCT00198978·377 enrolled

78 more indications

Mantle Cell Lymphoma5 trials

Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

Active, not recruiting·HHackensack Meridian Health·Phase 1·NCT02446236·27 enrolled

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

Active, not recruiting·EECOG-ACRIN Cancer Research Group·Phase 3·NCT03267433·689 enrolled

Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma

Completed· Takeda logo

Takeda·Phase 3·NCT00722137·487 enrolled

Show 2 more trials

Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma

Completed·SSt. Bortolo Hospital·Phase 2·NCT00992134·41 enrolled

Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma

Terminated·—·Phase 2·NCT01497275·5 enrolled

Nephrotic Syndrome4 trials

Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Nephrotic Syndrome

Recruiting·—·Phase 2·NCT05843968·46 enrolled

Rituximab in the First Episode of Paediatric Nephrotic Syndrome

Not yet recruiting·—·Phase 3·NCT05850546·138 enrolled

Efficacy of Anti-CD20 Ab Associated With Anti-CD38 in the Childhood Multidrug Dependent and Resistant Nephrotic Syndrome

Unknown status·IIstituto Giannina Gaslini·Phase 2·NCT05704400·20 enrolled

Show 1 more trial

Efficacy of Anti-CD20 Antibodies (Rituximab Biosimilar) in the Treatment of Childhood Steroid-dependent Nephrotic Syndrome

Terminated·IIstituto Giannina Gaslini·Phase 2·NCT04402580·30 enrolled

Rheumatoid Arthritis3 trials

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on One Prior Anti-TNF Therapy (RESET)

Completed· Roche logo

Roche·Phase 3·NCT01272908·120 enrolled

Evaluation of 200 mg of Rituximab Every 6 Months as Maintenance Treatment of Rituximab-treated Patients With Rheumatoid Arthritis

Recruiting·UUniversity Hospital, Strasbourg, France·Phase 4·NCT06906549·260 enrolled

Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)

Completed· Pfizer logo

Pfizer·N/A·NCT01643928·185 enrolled

Induction Therapy3 trials

Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate

Completed·UUniversity of Colorado, Denver·Phase 2·NCT01569451·53 enrolled

Phase II Study of Age-Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With MCL

Completed·FFondazione Italiana Linfomi - ETS·Phase 2·NCT01662050·57 enrolled

Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL

Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT01754857·36 enrolled

Leukemia3 trials

Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00087009·3 enrolled

Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents

Active, not recruiting·UUniversity Hospital Muenster·Phase 3·NCT03206671·650 enrolled

Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00472849·92 enrolled

Treatment3 trials

Risk Stratified Sequential Treatment for CD20-positive PTLD

Completed·—·Phase 2·NCT00590447·152 enrolled

Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL

Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·N/A·NCT07389356·70 enrolled

Treatment of ITP With Rituximab and / or Accutane

Unknown status·PPeking University People's Hospital·Phase 2·NCT02757196·112 enrolled

Immune Thrombocytopenia3 trials

Efficacy and Safety Assessment of a Treatment Combining Rituximab and Belimumab in Adults With Persistent Immune Thrombocytopenia

Completed·AAssistance Publique - Hôpitaux de Paris·N/A·NCT03154385·15 enrolled

Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07362199·20 enrolled

A Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）

Withdrawn·SShandong University·Phase 3·NCT02137681

Relapsed or Refractory2 trials

Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL

Unknown status·PProf. Dr. M. Dreyling (co-chairman)·Phase 3·NCT01449344·128 enrolled

Rituximab in Patients With Relapsed or Refractory TTP-HUS

Unknown status·HHamilton Health Sciences Corporation·Phase 2·NCT00531089·60 enrolled

Idiopathic Nephrotic Syndrome2 trials

Efficacy and Safety of Rituximab in the First Episode of Pediatric Idiopathic Nephrotic Syndrome

Completed·—·Phase 2·NCT04783675·44 enrolled

Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Idiopathic Nephrotic Syndrome.

Unknown status·IIstituto Giannina Gaslini·Phase 2·NCT04585152·160 enrolled

Multiple Sclerosis2 trials

Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis

Completed·AAnders Svenningsson·Phase 2·NCT01719159·23 enrolled

Intrathecal Rituximab in Progressive Multiple Sclerosis

Completed·—·Phase 2·NCT02545959·10 enrolled

Bullous Pemphigoid2 trials

Rituximab in the Treatment of Patients With Bullous Pemphigoid

Completed·—·Phase 1/2·NCT00286325·8 enrolled

Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid

Withdrawn·UUniversity of California, Davis·Phase 3·NCT04128176

Phase II2 trials

A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL

Completed·NNorthwestern University·Phase 2·NCT00858117·30 enrolled

A Phase II Study of the FIL on Elderly Frail Patients With DLBCL

Completed·FFondazione Italiana Linfomi - ETS·Phase 2·NCT02955823·68 enrolled

Macroglobulinemia2 trials

Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00005609

PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia

Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 1/2·NCT02971982·40 enrolled

Dexamethasone2 trials

Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for ITP

Completed·HHospital Universitario Dr. Jose E. Gonzalez·Phase 2·NCT01107951·21 enrolled

Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia

Recruiting·UUniversity College, London·Phase 2/3·NCT04061512·148 enrolled

MALT lymphoma2 trials

R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML)

Completed·KKonkuk University Medical Center·Phase 2·NCT01427114·33 enrolled

Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma

Active, not recruiting·IInternational Extranodal Lymphoma Study Group (IELSG)·Phase 2·NCT01808599·112 enrolled

Central Nervous System Lymphoma2 trials

Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma

Unknown status·MMingzhi Zhang·Phase 4·NCT04083066·20 enrolled

Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT02315326·93 enrolled

Tolerance2 trials

Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH

Active, not recruiting·MMassachusetts General Hospital·Phase 1·NCT04540380·20 enrolled

Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL

Completed·GGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea·Phase 2·NCT01562977·82 enrolled

Membranous Nephropathy2 trials

Efficacy and Safety of the Treatment of Primary Membranous Nephropathy: A Randomized Clinical Trial

Unknown status·RRenJi Hospital·N/A·NCT05532111·60 enrolled

Rituximab, Cyclophosphamide, and Corticosteroids in Primary Membranous Nephropathy

Recruiting·SSt. Petersburg State Pavlov Medical University·N/A·NCT05679336·40 enrolled

DLBCL2 trials

Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL

Unknown status·—·Phase 2·NCT01279902·32 enrolled

A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients

Unknown status·SSinocelltech Ltd.·Phase 3·NCT02772822·330 enrolled

Transplantation2 trials

Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.

Recruiting·KKim, Seok Jin·Phase 2·NCT04627753·30 enrolled

Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01010217·176 enrolled

Antibody-mediated Rejection2 trials

BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)

Active, not recruiting· Sanofi logo

Sanofi·Phase 2·NCT05156710·48 enrolled

Transplant Antibody-Mediated Rejection: Guiding Effective Treatments

Terminated·IImperial College London·Phase 3·NCT03994783·3 enrolled

CLL1 trial

Safe Accelerated Venetoclax Escalation in CLL

Active, not recruiting·—·Phase 1·NCT04843904·40 enrolled

Function1 trial

BR in Patients With CLL With Comorbidities and/or Renal Dysfunction

Completed·—·Phase 1·NCT01832922·8 enrolled

Relapse1 trial

BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL

Terminated·—·Phase 3·NCT02366663·3 enrolled

Myasthenia Gravis1 trial

A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis

Completed·FFredrik Piehl·Phase 3·NCT02950155·47 enrolled

Graft Versus Host Disease1 trial

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00691015·48 enrolled

Pilot Study1 trial

A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL

Active, not recruiting·HHuashan Hospital·Phase 1·NCT05036577·15 enrolled

Premature ovarian insufficiency1 trial

Immunomodulatory Therapy in Women With Autoimmune Premature Ovarian Insufficiency

Completed·AAngelica Lindén Hirschberg·Phase 2·NCT05586737·15 enrolled

Hodgkins lymphoma1 trial

HD18 for Advanced Stages in Hodgkins Lymphoma

Completed·UUniversity of Cologne·Phase 3·NCT00515554·1,500 enrolled

Membranoproliferative Glomerulonephritis1 trial

Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis

Completed·MMayo Clinic·Phase 1·NCT00275613·10 enrolled

Psoriatic Arthritis1 trial

Rituxan With or Without Methotrexate in Psoriatic Arthritis

Completed·SSwedish Medical Center·Phase 1·NCT00509678·6 enrolled

Primary Biliary Cirrhosis1 trial

B-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary Cirrhosis

Completed·NNewcastle-upon-Tyne Hospitals NHS Trust·Phase 2·NCT02376335·71 enrolled

TED1 trial

Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders

Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT03579875·48 enrolled

Hematopoietic Cell Transplant1 trial

Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00410982·145 enrolled

Efficacy and Safety1 trial

Long-Term Efficacy and Safety of CT-P10 in Patients With RA

Completed·CCelltrion·Phase 1·NCT01873443·87 enrolled

Lymphoproliferative Disease1 trial

Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy

Completed·DDiako Ev. Diakonie-Krankenhaus gemeinnützige GmbH·Phase 2·NCT02042391·60 enrolled

PrEP1 trial

Intensified Rituimab Prephase Before FCR in Untreated B-CLL

Completed·FFrench Innovative Leukemia Organisation·Phase 2·NCT01370772·140 enrolled

Hypophosphatasia1 trial

Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia

Withdrawn· AstraZeneca logo

AstraZeneca·Phase 4·NCT06015750

Desensitization1 trial

Evaluation of Desensitization Protocols in HLA-incompatible Kidney-transplant Candidates

Terminated·UUniversity Hospital, Grenoble·N/A·NCT03507348·8 enrolled

Monotherapy1 trial

Rituximab Monotherapy for EBV-HLH and CAEBV

Unknown status·—·Phase 3·NCT05384743·30 enrolled

IgA Nephropathy1 trial

A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy

Unknown status·XXIEJINGYUAN·Phase 4·NCT05824390·116 enrolled

Lenalidomide1 trial

Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue

Completed·AArbeitsgemeinschaft medikamentoese Tumortherapie·Phase 2·NCT01611259·50 enrolled

Renal Transplantation1 trial

De Novo Everolimus-based Therapy for Renal Transplantation Using Rituximab Induction

Terminated·NNational Taiwan University Hospital·Phase 4·NCT01312064·2 enrolled

Chidamide1 trial

A Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy

Unknown status·SSun Yat-sen University·Phase 2·NCT05527912·45 enrolled

Melanoma1 trial

Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy

Active, not recruiting·EEmory University·Phase 2·NCT03719131·15 enrolled

Aggressive B-cell NHL1 trial

Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00588094·20 enrolled

Mucous Membrane Pemphigoid1 trial

Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid

Recruiting·UUniversity Hospital, Rouen·Phase 3·NCT03295383·130 enrolled

B-cell non-Hodgkins lymphoma1 trial

A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma

Completed· Roche logo

Roche·Phase 1·NCT01290549·95 enrolled

Adult Acute Lymphoblastic Leukemia1 trial

Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia

Unknown status·—·Phase 2·NCT01429610·78 enrolled

Interstitial Lung Disease1 trial

Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease in Patients With Common Variable Immunodeficiency

Withdrawn·MMedical College of Wisconsin·Phase 2·NCT02789397

AIN1 trial

FCM Versus R-FCM Followed by R-Maintenance or Observation Only

Unknown status·LLudwig-Maximilians - University of Munich·Phase 3·NCT00317096·319 enrolled

B-Cell1 trial

Synergetic B-cell Immodulation in SLE

Completed·LLeiden University Medical Center·Phase 2·NCT02284984·16 enrolled

Elderly1 trial

BRIEF Bendamustine and Rituximab In Elderly Follicular

Terminated·TThe Lymphoma Academic Research Organisation·Phase 2·NCT01313611·62 enrolled

Hepatocellular Carcinoma1 trial

Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06301399·20 enrolled

Immunochemotherapy1 trial

ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT05290090·31 enrolled

Renal Transplant Rejection1 trial

Rituximab for Pediatric Renal Transplant Rejection

Completed·SStanford University·Phase 2/3·NCT00697996·20 enrolled

Chemotherapy1 trial

Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over

Unknown status·PPusan National University Hospital·Phase 2·NCT02792491·57 enrolled

Maintenance Therapy1 trial

RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL

Recruiting·NNational Research Center for Hematology, Russia·Phase 2·NCT05425654·30 enrolled

Pemphigus1 trial

Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe Pemphigus

Unknown status·UUprety Shraddha·Phase 3·NCT01974518·20 enrolled

Methylprednisolone1 trial

High-dose Methylprednisolone and Rituximab in High Risk B-CLL

Completed·VVilnius University·Phase 2·NCT00558181·29 enrolled

Type 1 Diabetes1 trial

Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes

Active, not recruiting·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT03929601·74 enrolled

Observational Study1 trial

The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders

Completed·UUniversity Hospital, Toulouse··NCT00960713·35 enrolled

Renal Allograft Recipients1 trial

Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00307125·757 enrolled

Intravenous1 trial

RITUXIMAB BS Intravenous Infusion 100mg・500mg [Pfizer] Post-marketing Database Study

Completed· Pfizer logo

Pfizer··NCT06790420·1 enrolled

High Risk Patients1 trial

Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL.

Completed·GGruppo Italiano Terapie Innovative nei Linfomi·Phase 3·NCT00355199·246 enrolled

Hematological Malignancies1 trial

Study Evaluating Venetoclax in Subjects With Hematological Malignancies

Completed· AbbVie logo

AbbVie·Phase 1/2·NCT02265731·38 enrolled

Sickle Cell Disease1 trial

Siplizumab for Sickle Cell Disease Transplant

Terminated·—·Phase 1/2·NCT06078696·1 enrolled

Tics1 trial

Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab

Completed·UUniversity Hospital, Toulouse·Phase 4·NCT00820469·20 enrolled

First Line Therapy1 trial

Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL

Recruiting·ZZhejiang Cancer Hospital·N/A·NCT06832267·44 enrolled

ILD1 trial

Rituxmab Versus IL-6 in Treating ILD

Completed·—·Phase 2/3·NCT05963048·60 enrolled

Vasculitis1 trial

Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing

Terminated·MMassachusetts General Hospital·Phase 4·NCT02749292·115 enrolled

Kidney1 trial

Trial of Rituximab Given Pre-Transplant to Sensitised Live Donor Kidney Recipients

Unknown status·HHunter and New England Health·Phase 2·NCT00371904·192 enrolled

Focal Segmental Glomerulosclerosis1 trial

Rituximab in Multirelapsing Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS)

Completed· Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research·Phase 3·NCT00981838·24 enrolled

Monoclonal Gammopathy1 trial

Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance

Terminated·MMayo Clinic·Phase 2·NCT00588822·21 enrolled

Immunotherapy1 trial

Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL

Withdrawn·NNorthwestern University·Phase 1·NCT00734773

Pompe Disease1 trial

An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease

Completed· Sanofi logo

Sanofi·Phase 4·NCT00701129·4 enrolled

Waldenstrom macroglobulinemia1 trial

Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma

Completed·MMayo Clinic·Phase 2·NCT00711828·21 enrolled

Unspecified1 trial

Rituximab (RTX) Therapy in Patients With Active TAO

Completed·GGöteborg University·Phase 4·NCT02378298·38 enrolled

Regulatory

FDA Approval Timeline[5]

Nov 26, 1997

Rituxan

BLA 103705

Nov 26, 1997

RITUXAN

BLA BLA103705

Sources

References

[1]
ClinicalTrials.gov — 1824 trial records for Rituximab. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Rituxan drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Rituximab compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Rituximab. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (BLA 103705). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: B-Lymphocyte Antigen CD20 Binding Agent[3]
Modality: Monoclonal antibody[3]
Highest Phase: Approved[1]
Company: Roche